Former Akero executives team up with Fairmount to launch new immunology company
The former executive team of Akero Therapeutics, which was recently acquired by Novo Nordisk, has announced the formation of a new immunology-focused company. They are partnering with investment firm Fairmount to fund the venture.
The new company aims to develop therapies targeting immune‑mediated diseases, leveraging the team’s experience in antibody and cell‑based modalities.
In related industry news, AstraZeneca disclosed a $600 million upfront payment to secure global rights to the lung‑cancer drug Zegfrovy from China’s Dizal Pharmaceutical. Zegfrovy, an EGFR inhibitor approved in the U.S. and China for certain advanced non‑small cell lung cancer patients, is now under regulatory review as a potential first‑line treatment.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Akero team, backed by Fairmount, launches new immunology company”
read at STAT ↗
comments(0)
5-min edit window · permanent after that